30th Mar 2026 07:00
Arecor Therapeutics plc("Arecor" or the "Company")
Notice of FY25 Results
Cambridge, UK, 30 March 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, will announce its full year results for the twelve months ended 31 December 2025 on Monday 13 April 2026.
Dr Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will host a webcast and Q&A for analysts and institutional investors at 9.30am UK time on Monday 13 April 2026. To register, please contact [email protected].
For private investors, there will be a presentation via the Investor Meet Company platform at 11.00am UK time on Thursday 23 April 2026. To register, please see https://www.investormeetcompany.com/companies/arecor-therapeutics-plc.
Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am UK time on 22 Apr 2026 or during the live presentation. Investors who follow Arecor on the Investor Meet Company platform will automatically be invited.
A copy of the full year results presentation will be released on the Company website at https://arecor.com/investor-centre/financial-information/ after the meeting on 13 April 2026.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc Dr Sarah Howell, Chief Executive OfficerDavid Ellam, Chief Financial Officer |
+44 (0) 1223 426060 |
Singer Capital Markets Advisory LLP(NOMAD and Broker) Phil Davies, James Fischer |
+44 (0) 20 7496 3000 |
Vigo Consulting (Financial Communications) Melanie Toyne-Sewell, Rozi Morris | +44 (0) 20 7390 0230 |
Vida Strategic Partners (US Investor Relations) Stephanie Diaz | +1 (415) 675-7401 |
Notes to Editors
About Arecor
Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.
Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel's twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target.
The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com.
Arecor® and Arestat® are registered trademarks of Arecor Limited.
Related Shares:
Arecor Therape